{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:50:18Z","timestamp":1774936218173,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by the proliferation of fibrous tissue in the bone marrow. Transformation to acute leukemia, typically acute myeloid leukemia, represents a terminal event in its natural history; however, transformation to mixed phenotype acute leukemia (MPAL) is exceedingly rare. The diagnosis and treatment of MPAL are particularly challenging, especially in elderly patients with underlying MF. The clinical characteristics, treatment response, and prognosis of such cases remain unclear and are rarely reported.<\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n \n This article presents a retrospective analysis of a 75-year-old female patient who initially presented in October 2023 with splenomegaly and thrombocytopenia. Based on bone marrow morphology, biopsy (revealing Grade MF-2 fibrosis), and molecular testing (detecting a\n JAK2<\/jats:italic>\n V617F<\/jats:sup>\n mutation with a variant allele frequency of 44.67% and an\n ASXL1<\/jats:italic>\n mutation), a diagnosis of primary myelofibrosis (PMF) was established. The patient did not receive standard targeted therapy and was subsequently lost to follow-up. Approximately two years later (September 2025), she was readmitted due to a significantly elevated white blood cell count (47.14 \u00d7 10\n 9<\/jats:sup>\n \/L) with 64% blasts in the peripheral blood. A comprehensive re-evaluation using MICM (Morphology, Immunology, Cytogenetics, Molecular) classification was performed: bone marrow flow cytometry revealed that 65.73% of the blasts co-expressed CD34, CD117, and the T-lineage marker CD7. Molecular testing detected the persistence of the original\n JAK2<\/jats:italic>\n and\n ASXL1<\/jats:italic>\n mutations, with the acquisition of additional\n NRAS<\/jats:italic>\n ,\n EZH2<\/jats:italic>\n , and\n TET2<\/jats:italic>\n mutations. A definitive diagnosis of MPAL (T\/Myeloid mixed phenotype) transformed from PMF was established. Given the patient\u2019s advanced age and underlying MF, two cycles of a low-intensity chemotherapy regimen primarily based on the \u201cVP regimen (Vincristine + Prednisone) combined with Azacitidine\u201d were administered. Initial treatment resulted in a complete remission with incomplete hematologic recovery (CRi). Considering the incomplete recovery of peripheral blood platelets and the presence of minimal residual blasts detected by bone marrow flow cytometry, the patient was started on a regimen combining the VP regimen with a VA regimen chemotherapy to achieve a deep and durable complete remission. As of the latest follow-up, the patient\u2019s relevant laboratory results remain within a safe range, with no peripheral blasts detected. Her psychological and physiological status is acceptable, she reports no specific discomfort, and her disease is well-controlled.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n \n This rare case offers several critical insights: 1) Rare Transformation Type: It clearly delineates the complete clinical and molecular evolutionary trajectory of PMF transforming into the rare MPAL, underscoring the importance of precise immunophenotyping during the blast phase of MF to identify atypical transformations. 2) Clonal Evolution Pattern: The molecular profile evolved from typical MPN driver mutations (\n JAK2<\/jats:italic>\n ,\n ASXL1<\/jats:italic>\n ) to the acquisition of additional mutations associated with leukemic transformation (\n NRAS<\/jats:italic>\n ,\n EZH2<\/jats:italic>\n ,\n TET2<\/jats:italic>\n ), providing a concrete example for understanding the genetic mechanisms underlying such transformations. 3) Treatment Dilemma in the Elderly: The case highlights the immense therapeutic challenges in elderly MPAL patients with concomitant persistent myelofibrosis. While low-intensity regimens may induce short-term remission, the responses are not durable. Patient tolerability to intensive chemotherapy and novel targeted agents (e.g., Venetoclax) is poor, leading to a dismal prognosis. 4) Management Implications: It emphasizes the necessity of long-term, regular follow-up and early intervention for MF patients, particularly those harboring high-risk mutations. Furthermore, it underscores the urgent need for more effective and better-tolerated novel therapies for this patient population.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Transformation of MF to MPAL is a rare event associated with an poor prognosis. This study provides the detailed report of an elderly patient with MPAL arising from\n JAK2<\/jats:italic>\n -positive PMF. This case not only serves as a unique model illustrating the complex evolution of a malignant clone but also profoundly reveals the unique therapeutic challenges and extremely poor survival outcome resulting from the convergence of advanced age, MF background, and MPAL transformation. It offers pivotal real-world evidence for the clinical management of this specific patient population and highlights the need to explore novel therapeutic strategies.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1811409","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:13:04Z","timestamp":1774930384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: The diagnostic and therapeutic crossroads: when myelofibrosis transforms into mixed phenotype acute leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanquan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, Ganzhou People\u2019s Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Jiangxi Health Commission Key Laboratory of Leukemia","place":["Ganzhou, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ganzhou People\u2019s Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Jiangxi Health Commission Key Laboratory of Leukemia","place":["Ganzhou, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangzhou","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ganzhou People\u2019s Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Jiangxi Health Commission Key Laboratory of Leukemia","place":["Ganzhou, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ganzhou People\u2019s Hospital (The Affiliated Ganzhou Hospital of Nanchang University), Jiangxi Health Commission Key Laboratory of Leukemia","place":["Ganzhou, Jiangxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1516881","article-title":"Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis","volume":"60","author":"Selicean","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03335-7","article-title":"Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives","volume":"115","author":"Loscocco","year":"2022","journal-title":"Int J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05920-8","article-title":"Myeloproliferative neoplasms: young patients, current data and future considerations","volume":"103","author":"Sobas","year":"2024","journal-title":"Ann Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.01.001","article-title":"Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia","volume":"13","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000502121","article-title":"Post-myelofibrosis acute myeloid leukemia effectively treated with a combination of ruxolitinib and 5-azacytidine","volume":"42","author":"Diamantopoulos","year":"2019","journal-title":"Oncol Res Treat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","article-title":"Mixed phenotype acute leukemia: current approaches to diagnosis and treatment","volume":"23","author":"Alexander","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2017.013","article-title":"Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment","volume":"161","author":"Cernan","year":"2017","journal-title":"BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semdp.2025.150893","article-title":"An update on mixed phenotype acute leukemia","volume":"42","author":"Weinberg","year":"2025","journal-title":"Semin Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.289","article-title":"Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia","volume":"29","author":"Engle","year":"2015","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061785","article-title":"Use of next generation sequencing to define the origin of primary myelofibrosis","volume":"15","author":"Visani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00872","article-title":"Persistent basophilia may suggest an \u201cAccelerated phase\u201d in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia","author":"Dobrowolski","year":"2019","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0218-RA","article-title":"Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls","volume":"141","author":"Charles","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1628767","article-title":"Successful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP\/myeloid mixed-phenotype acute leukemia: a case report","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000519882","article-title":"Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B\/myeloid mixed-phenotype acute leukemia and relapsed\/refractory acute myeloid leukemia: A report of 3 cases","volume":"67","author":"Wang","year":"2022","journal-title":"Chemotherapy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1693061","article-title":"Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review","volume":"15","author":"Mi","year":"2025","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05644-9","article-title":"Successful treatment of a B\/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab","volume":"103","author":"Liu","year":"2024","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2527018","article-title":"Chemotherapy-free treatment of B-lymphoid\/myeloid mixed phenotype acute leukemia: two case reports and literature review","volume":"17","author":"Wang","year":"2025","journal-title":"Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.300161","article-title":"A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia","author":"Zhang","year":"2026","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1715087","article-title":"Mixed phenotype acute leukemia, the dissection of an enigmatic disease in the era of novel therapies","volume":"13","author":"Karasek","year":"2025","journal-title":"Front Pediatr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811409\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:13:26Z","timestamp":1774930406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811409\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1811409"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1811409","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1811409"}}